Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel Sells $142,495.50 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson sold 4,965 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.70, for a total value of $142,495.50. Following the completion of the sale, the general counsel now directly owns 107,756 shares of the company’s stock, valued at $3,092,597.20. The trade was a 4.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Apellis Pharmaceuticals Trading Up 2.4 %

Apellis Pharmaceuticals stock opened at $29.73 on Friday. The firm has a market cap of $3.70 billion, a PE ratio of -14.65 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $71.90. The stock’s 50 day simple moving average is $31.88 and its two-hundred day simple moving average is $33.42. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. During the same period last year, the company posted ($1.17) earnings per share. The business’s quarterly revenue was up 78.3% on a year-over-year basis. Analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.73 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Bank of America lowered their price target on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Oppenheimer dropped their target price on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. William Blair assumed coverage on shares of Apellis Pharmaceuticals in a report on Wednesday, October 16th. They issued an “outperform” rating for the company. Scotiabank dropped their price objective on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 6th. Finally, Piper Sandler cut their target price on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.65.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of APLS. Wolverine Asset Management LLC purchased a new position in Apellis Pharmaceuticals during the third quarter worth approximately $27,000. True Wealth Design LLC acquired a new position in shares of Apellis Pharmaceuticals during the 3rd quarter worth approximately $27,000. Capital Performance Advisors LLP purchased a new position in shares of Apellis Pharmaceuticals during the 3rd quarter valued at approximately $56,000. KBC Group NV grew its stake in Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after acquiring an additional 679 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after acquiring an additional 781 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).